4 European Projects Found
Searched on 125080 European Projects
FINISHED
New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent (KALADRUG-R)
Start date: Nov 1, 2008, End date: Apr 30, 2013,
...isceral leishmaniasis (VL), one of the most-neglected infectious diseases, has an annual incidence of 500,000 cases. Early treatment is a major pillar of the current program for VL elimination on the Indian sub-continent. However, the arsenal of available drugs is very limited, and their use is jeopardized by drug resistance. Combination regimens for VL are under clinical development, but it will ...
Read Project
10
Partners Participants
FINISHED
Signalling in life cycle stages of malaria parasites (MALSIG)
Start date: Feb 1, 2009, End date: Jul 31, 2012,
...ynamics (trafficking, transporters) Approaches will include proteomics, reverse genetics, structural biology, and the use of animal models of malaria. The consortium is constituted of EU and Indian partners with a proven track record either in research into one of the developmental stages/processes described above, or in signal transduction in malaria parasites. The project will significantly st ...
Read Project
18
Partners Participants
FINISHED
"PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials" (RAPSODI)
Start date: Jan 1, 2009, End date: Jun 30, 2012,
"The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedure ...
Read Project
9
Partners Participants
FINISHED
Development of a DNA vaccine for visceral leishmaniasis (LEISHDNAVAX)
Start date: Jan 1, 2009, End date: Jun 30, 2012,
"This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be se ...
Read Project
